CBFB-MYH11 hypomethylation signature and PBX3 differential methylation revealed by targeted bisulfite sequencing in patients with acute myeloid leukemia

Table 1 Characteristics of AML patients

Sample ID	Genetic aberration	Clinical characterization	FAB subtype	Gender	Material	% blasts
AML_1	CBFB-MYH11, FLT3- ITD	de novo AML	AML M4	male	BM	68
AML_2	CBFB-MYH11	de novo AML	AML M4	female	PB	40
AML_3	NPM1	therapy-related AML*	AML M1	female	PB	67
AML_4	MLL-PTD	therapy-related AML*	AML M4	female	BM	42
AML_5	NPM1, DNMT3A, FLT3- ITD	AML with multilineage dysplasia	AML M2	female	PB	58
AML_6	none	AML with multilineage dysplasia	AML M1	female	BM	82
AML_7	NPM1, DNMT3A, FLT3- ITD	de novo AML	AML M4	male	BM	94
AML_8	FLT3- ITD	de novo AML	AML M1	male	BM	87
AML_9	FLT3- ITD	de novo AML	AML M1	male	BM	89
AML_10	NPM1, FLT3- ITD	de novo AML	AML M2	female	BM	75
AML_11	MLL-PTD	de novo AML	AML M1	male	BM	92
AML_12	MLL-PTD, CEBPA	de novo AML	AML M1	female	PB	80
AML_13	NPM1, CEBPA	AML after MDS	AML M6	male	PB	60
AML_14	none	AML after MDS	AML M2	male	PB	44
CD34+		pool of 4 CD34+ healthy control cells		males

AML_1 to AML_14 are AML patients at diagnosis that were subjected to targeted bisulfite sequencing and gene expression profiling; CD34+ is a healthy control's pool; ^*after breast cancer; BM - bone marrow, PB - peripheral blood.

ISSN: 1756-8722